Immunome Shares Rise 16% After Acquisition of Potential Tumor Treatment From Ayala Pharmaceuticals
Immunome Shares Rise 16% After Acquisition of Potential Tumor Treatment From Ayala Pharmaceuticals
收購阿亞拉制藥的潛在腫瘤治療藥物後,Immunome股價上漲了16%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊